BioSpace News Archive

Novo Nordisk and Evotec SE, today announced LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics.

Axial Therapeutics today announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead product candidate, AB-2004, a first-in-class oral gut-targeted small molecule therapeutic designed to treat irritability associated with autism.

Inspire Medical Systems, Inc. announced key events at the International Surgical Sleep Society and American Academy of Otolaryngology meetings in Nashville, TN, September 29 through October 4.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today announced that it has completed patient enrollment in its Phase 1 clinical trial (NCT03978689) evaluating CUE-101.

Candel Therapeutics, Inc. today announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy.

IN8bio, Inc., a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is proud to announce its upcoming Research & Development Day on Thursday, October 12, 2023.

Motus GI Holdings, Inc., a medical technology company focused on improving endoscopic outcomes and experiences, announced that it has submitted a special 510 to the U.S. Food and Drug Administration for market clearance of its Pure-Vu Gen 4 Gastro and Colon.

Vaccinex, Inc., a clinical-stage biotechnology company will report on novel findings for its lead product, pepinemab, with implications for treatment of Alzheimer’s and other slowly progressive neurodegenerative diseases and for cancer immunotherapy at two upcoming Medical Conferences.

Heligenics, Inc., a pioneering biotechnology company applying functional genomics to drug discovery, announced that it has reshaped the landscape of interferon beta drugs which are widely-prescribed for Multiple Sclerosis.

Liminal BioSciences Inc. is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP, a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier.